NCT04215809View on ClinicalTrials.gov

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

PHASE1RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

June 30, 2027

Conditions
CLL/SLL
Interventions
DRUG

Lisaftoclax

Lisaftoclax investigation drug in ramp up dosing

Trial Locations (9)

3199

RECRUITING

Frankston Private Hospital, Melbourne

28204

RECRUITING

Novant Health, Charlotte

32224

RECRUITING

Mayo Clinic, Jacksonville

44195

RECRUITING

Cleveland Clinic, Cleveland

44718

RECRUITING

Gabrail Cancer Center, Canton

91010

RECRUITING

City of Hope, Duarte

98122

RECRUITING

Swedish Health, Seattle

02215

RECRUITING

Dana Farber Cancer Institute, Boston

QLD 4102

RECRUITING

Princess Alexandria Hospital, Brisbane

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT04215809 - Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | Biotech Hunter | Biotech Hunter